These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30950845)

  • 1. Multiple sclerosis: clinical trial design 2019.
    Pardini M; Cutter G; Sormani MP
    Curr Opin Neurol; 2019 Jun; 32(3):358-364. PubMed ID: 30950845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.
    Hyland M; Rudick RA
    Curr Opin Neurol; 2011 Jun; 24(3):255-61. PubMed ID: 21455068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remyelination in multiple sclerosis: from concept to clinical trials.
    Kremer D; Göttle P; Flores-Rivera J; Hartung HP; Küry P
    Curr Opin Neurol; 2019 Jun; 32(3):378-384. PubMed ID: 30865009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of methodological issues of clinical trials in multiple sclerosis.
    Montalban X
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S35-42. PubMed ID: 22206765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying treatments for progressive multiple sclerosis.
    Comi G
    Mult Scler; 2013 Oct; 19(11):1428-36. PubMed ID: 24062415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The changing face of multiple sclerosis clinical trial populations.
    Uitdehaag BM; Barkhof F; Coyle PK; Gardner JD; Jeffery DR; Mikol DD
    Curr Med Res Opin; 2011 Aug; 27(8):1529-37. PubMed ID: 21671851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocrelizumab: its efficacy and safety in multiple sclerosis.
    Juanatey A; Blanco-Garcia L; Tellez N
    Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aggressive multiple sclerosis. Definition and specific therapeutic indication].
    Edan G
    Presse Med; 2004 Feb; 33(3):187-91; discussion 192. PubMed ID: 15029034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials in multiple sclerosis: methodological issues.
    Comi G; Filippi M
    Curr Opin Neurol; 2005 Jun; 18(3):245-52. PubMed ID: 15891407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic options for multiple sclerosis.
    Curtin F; Hartung HP
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?
    Graetz C; Groppa S; Zipp F; Siller N
    Expert Rev Neurother; 2018 Mar; 18(3):203-219. PubMed ID: 29411688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An update on the treatment options for multiple sclerosis].
    Niino M
    Brain Nerve; 2012 Dec; 64(12):1421-6. PubMed ID: 23209069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.